Samuel Jacques

Samuel Jacques is a Synthetic Biologist specializing in drug discovery and biomanufacturing, currently serving as a Senior Scientist at TATUM Bioscience, where they focus on producing nanofilaments for cancer immunotherapies. Samuel holds a Ph.D. in Molecular Biology, as well as a Graduate Diploma in Business Administration and Management. Previously, they have held positions at the University of Toronto as a Postdoctoral Fellow and at various organizations, including Ginkgo Bioworks and GuardRx, where they supervised a COVID-19 diagnostic lab. Their research has been published in high-impact journals, and they have contributed to the development of lead compounds aimed at treating leukemia and COVID-19.